| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
| severe uncontrolled asthma |
|
| E.1.1.1 | Medical condition in easily understood language |
| Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that episodes of breathing difficulty are still occurring despite the use of other available treatments |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
| MedDRA Classification |
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.0 |
| E.1.2 | Level | LLT |
| E.1.2 | Classification code | 10049106 |
| E.1.2 | Term | Asthma chronic |
| E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.0 |
| E.1.2 | Level | PT |
| E.1.2 | Classification code | 10003553 |
| E.1.2 | Term | Asthma |
| E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
| E.1.3 | Condition being studied is a rare disease | No |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
| To determine the effect of benralizumab on the rate of asthma exacerbations |
|
| E.2.2 | Secondary objectives of the trial |
To determine the effect of benralizumab on:
- patient-reported disease-specific quality of life.
- lung function.
- patient-reported asthma control.
- time to first asthma exacerbation.
- lung function at home.
- general quality of life and health status.
To evaluate patient impression of overall asthma severity and change in the overall asthma status.
To determine the effect of benralizumab on the patient’s predominant symptoms and disease specific health-related quality of life in patients with doctor diagnosed chronic sinusitis with nasal polyposis.
Safety Objective: To assess the safety and tolerability of benralizumab
Exploratory Objectives:
To determine the effect of:
-eosinophil depletion with benralizumab on Biomarker components of known asthma inflammatory pathways or airway remodeling and Biomarker surrogates of eosinophilic inflammation/activation
-benralizumab on the patient’s level of asthma control based on standard asthma guidance recommendations |
|
| E.2.3 | Trial contains a sub-study | Yes |
| E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
ANDHI in Practice [ANDHI IP] substudy included within study and
Protocol Amendment 4.0, 01 May 2020.
Main objective: To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen while
maintaining asthma control.
Main outcome variables:
- Number of reductions in asthma controller medications from Visit 15 to the end of study (EOS) Visit 27 (Day 560/Week 80).
- Number of adapted GINA step category reductions from baseline at
Visit 15 to the EOS Visit 27 (Day 560/Week 80).
Main outcome measures:
-Proportion of patients with at least one reduction in asthma controller medication from Visit 15 to EOS (Visit 27);
- Proportions of patients with the number of adapted GINA step category reductions from Visit 15 to EOS (Visit 27) ≥ X, where X is ranging from 1 to 4.
- Distribution of the number of adapted GINA step reductions from Visit 15 to EOS (Visit 27) (X) where X is ranging from 0c to 4.
Other Objectives: To assess standard asthma efficacy measures for
benralizumab treated patients when reducing their standard of care
asthma controller regimen.
Supportive Measures:
- Change in continuous asthma efficacy measures (including ACQ6,
SGRQ, pre-bronchodilator forced expiratory volume [pre-BD FEV1] and
weekly mean morning peak expiratory flow [PEF]) from Visit 15 to the
EOS Visit 27 (Day 560/Week 80).
- Change in continuous asthma efficacy measures(including ACQ6, SGRQ,
FEV1 and morning PEF) from Visit 4 to the EOS Visit 27 (Day 560/Week
80).
- Degree of change reported by the patient (PGI-C) from Visit 13 and
Investigator (CGI-C) from Visit 4 to the EOS Visit 27 (Day 560/Week
80).
- Clinically significant asthma exacerbations from Visit 15 to the EOS
Visit 27 (exacerbation count and time to first exacerbation).
Safety Objective: To assess the safety and tolerability of benralizumab during treatment period.
Endpoint: AEs, physical examination, vital signs during the open label
benralizumab treatment period (Visit 13 to Visit 27). |
|
| E.3 | Principal inclusion criteria |
1.Written informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union(EU) guidelines. 2.Female and male patients aged 18 to 75 years inclusively at the time of Visit 1 with a history of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS plus asthma controller, for at least 12 months prior to Visit 1. Other acceptable asthma controllers include a long acting bronchodilator(LABA or long acting muscarinic antagonists [LAMA]),a leukotriene inhibitor, theophylline preparations or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control; maximum total daily dose 20 mg prednisone or equivalent). 3.Documented current treatment with high daily doses of ICS plus at least one other asthma controller for at least 3 months prior to Visit 1; see inclusion criterion 2 for acceptable other asthma controllers. For ICS/LABA combination preparations, highest-strength maintenance doses approved in the given country will meet this criterion. If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose. 4.History of at least 2 asthma exacerbations while on ICS plus another asthma controller(see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids(IM, IV, or oral) in the 12 months prior to Visit 1. For patients receiving corticosteroids as a maintenance therapy, the corticosteroid treatment for the exacerbation is defined as a temporary increase of their maintenance dose. 5.ACQ6 score ≥1.5 at Visit 1. 6.Screening pre-bronchodilator (pre-BD) FEV1 of <80% predicted at Visit 2 Note: Spirometry testing should only be performed if the patient meets the asthma medication hold for lung function testing, the test should be postponed to another day prior to Visit 3 to improve the chances of achieving a qualifying FEV1 that is not affected by bronchodilator medication.
7.Evidence of asthma as documented by excessive variability in lung function by satisfying ≥1 of the criteria below: a)Airway reversibility(FEV1 ≥12%)using a short-acting bronchodilator demonstrated at Visit 2 or Visit 3. b)Airway reversibility to short-acting bronchodilator(FEV1 ≥12%)documented* during the 12 months prior to enrolment Visit 1.c)Daily diurnal peak flow variability of >10% when averaged over 7 continuous days during the study run-in period. d)An increase in FEV1 of ≥12% and 200 mL after a therapeutic trial of systemic corticosteroid eg, OCS), given outside of an asthma exacerbation, documented in the 12 months prior enrolment Visit 1. e)Airway hyper-responsiveness documented in the 24 months prior to randomization Visit4. 8.Peripheral blood eosinophil count either: ≥300 cells/μL assessed by central laboratory at either Visit 1 or Visit 2 OR ≥150 to <300 cells/μL assessed by central laboratory at either Visit 1 or Visit 2, IF ≥1 of the following 5 clinical criteria (a to e)is met: a)Using maintenance OCS daily or every other day OCS requirement in order to maintain asthma control; maximum total daily dose 20 mg prednisone or equivalent)at screening. b)History of nasal polyposis. c)Age of asthma onset ≥18 years. d)Three or more documented exacerbations requiring systemic corticosteroid treatment during the 12 months prior to screening. e)Prebronchodilator forced vital capacity <65% of predicted, as assessed at Visit 2.
9.Women of childbearing potential(WOCBP) must use at least one acceptable and effective form of birth control (confirmed by the Investigator), eg,total sexual abstinence when this is in line with the preferred and usual lifestyle of the patient(periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception), a vasectomized sexual partner, Implanon®, female sterilization by tubal occlusion, any effective Intrauterine device/Levonorgestrel Intrauterine system, Depo-Provera™ injections,oral contraceptive, and Evra Patch™ or Nuvaring™. Women of childbearing potential must agree to use birth control, as defined above, from enrolment, throughout the study duration and until 16 weeks(approximately 5 half-lives)after last dose of investigational product(IP). Women of childbearing potential must also have negative serum pregnancy test result on Visit 1.
10.Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy),or who are postmenopausal. 11.All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.
12.Weight of ≥40 kg. For Inclusion Criteria for ANDHI in Practice Sub Study please see Page 47 of protocol. |
|
| E.4 | Principal exclusion criteria |
1.Clinically important pulmonary disease other than asthma (eg, active lung infection, chronic obstructive pulmonary disease [COPD], bronchiectasis, pulmonary fibrosis, cystic fibrosis), or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
2.Acute upper or lower respiratory infections within 30 days prior to the date informed consent is obtained or during the screening/run-in period.
3.Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Affect the safety of the patient throughout the study.
Influence the findings of the studies or their interpretations.
Impede the patient’s ability to complete the entire duration of study.
4.Known history of allergy or reaction to any component of the IP formulation.
5.A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy.
6.Any clinically significant abnormal findings in physical examination, vital signs, hematology, or clinical chemistry during screening period, which in the opinion of the Investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient’s ability to complete entire duration of the study.
7.Any clinically significant cardiac disease or any electrocardiogram (ECG) abnormality obtained during the screening/run-in period, which in the opinion of the Investigator may put the patient at risk or interfere with study assessments.
8.History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained.
9.A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
10.Current smokers or former smokers with a smoking history of ≥10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1.
11.Current malignancy, or history of malignancy, except for:
Patients who have had non-melanoma skin cancers or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent is obtained.
Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent is obtained.
12.Approved or off-label use of systemic immunosuppressive medications within 3 months prior to the date informed consent is obtained. These include but are not limited to small molecules such as methotrexate, cyclosporine, azathioprine, and immunosuppressive/immunomodulating biologics such as tumor necrosis factor (TNF) blockers. Regular use of systemic (oral) corticosteroids is also excluded except for the indication of asthma.
13.Concurrent biologics for asthma are not allowed except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of Visit 1). Acceptable washout periods for other asthma biologics: Other eosinophil lowering products indicated for asthma (including mepolizumab or reslizumab): at least 4 months.Prior omalizumab use: at least 1 month.
14.Previously received benralizumab (MEDI-563).
15.Receipt of any investigational medication as part of a research study within approximately 5 half-lives prior to randomization.
16.ALT or AST level >3 times the upper limit of normal (ULN) confirmed during screening period.
17.Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.
18.Receipt of live attenuated vaccines 30 days prior to the date of randomization; other types of vaccines are allowed.
19.Planned surgical procedures during the conduct of the study.
20.Currently breastfeeding or lactating women.
21.Pevious randomization in the present study.
22.Concurrent enrolment in another interventional or post-authorization safety study.
23.AstraZeneca staff involved in the planning and/or conduct of the study.
24.Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals.
individuals.
For Exclusion Criteria for ANDHI in Practice Sub Study please see Page 50 of protocol. |
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
| The annualized rate of asthma exacerbations between benralizumab and placebo. |
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
| Treatment period of 24 weeks. |
|
| E.5.2 | Secondary end point(s) |
The change from baseline (Visit 4) in Saint George Respiratory Questionnaire (SGRQ) to the EOT (Day 168/Week 24).
The change from baseline (Visit 4) in forced expiratory volume in first second (FEV1) over the treatment period (up to and including Day 168/Week 24).
The change from baseline (Visit 4) in Asthma Control Questionnaire 6 (ACQ6) to the EOT (Day 168/Week 24).
Time to first asthma exacerbation (treatment period 24 weeks).
The change from run-in baseline morning peak expiratory flow (PEF) to the EOT (Day 168/Week 24).
The change from baseline (Visit 4) SF 36v2 to the EOT (Day 168/Week 24).
The change from baseline (Visit 4) in PGI-S to the EOT (Day 168/Week 24).
The degree of change reported by the patient (PGI-C) and Investigator (CGI-C) expressed as a proportion of each of the 7 possible responses to the EOT (Day 168/Week 24).
The degree of change reported by the patient in their predominant symptom to the EOT (Day 168/Week 24).
The change from baseline (Visit 3) in the sino-nasal outcome test (SNOT-22) score to the EOT (Day 168/Week 24).
Safety: Adverse events (AEs), laboratory variables, physical examination.
Exploratory:
The change from baseline (Visit 4) in circulating biomarkers to each pre-specified scheduled assessment during the treatment period.
The proportion of time that that the patient’s asthma is well-controlled based on composite diary measures. |
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
From Baseline (Visit 4) to EOT (Day 168/ Week 24).
Throughout 24 week treatment period. |
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | No |
| E.6.7 | Pharmacodynamic | Yes |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | No |
| E.6.10 | Pharmacogenetic | No |
| E.6.11 | Pharmacogenomic | No |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | Yes |
| E.6.13.1 | Other scope of the trial description |
|
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | No |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | No |
| E.7.1.3.1 | Other trial type description | |
| E.7.2 | Therapeutic exploratory (Phase II) | No |
| E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | Yes |
| E.8.1.1 | Randomised | Yes |
| E.8.1.2 | Open | No |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | Yes |
| E.8.1.5 | Parallel group | Yes |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | Yes |
| E.8.1.7.1 | Other trial design description |
| Double blind for 24 week period. Patients can then be enrolled in 56 week open label sub study. |
|
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | No |
| E.8.2.2 | Placebo | Yes |
| E.8.2.3 | Other | No |
| E.8.2.4 | Number of treatment arms in the trial | 2 |
| E.8.3 |
The trial involves single site in the Member State concerned
| No |
| E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
| E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 118 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | No |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Austria |
| Belgium |
| Canada |
| Denmark |
| Finland |
| France |
| Germany |
| Italy |
| Netherlands |
| Norway |
| Spain |
| Sweden |
| Switzerland |
| United Kingdom |
| United States |
|
| E.8.7 | Trial has a data monitoring committee | No |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
| The last visit of the last patient undergoing the study’. The final study visit will be the telephone FU Visit. |
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 3 |
| E.8.9.1 | In the Member State concerned months | 0 |
| E.8.9.1 | In the Member State concerned days | 0 |
| E.8.9.2 | In all countries concerned by the trial years | 3 |
| E.8.9.2 | In all countries concerned by the trial months | 0 |
| E.8.9.2 | In all countries concerned by the trial days | 0 |
Print
